alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
[Federal Register Volume 60, Number 96 (Thursday, May 18, 1995)]
[Notices]
[Page 26723]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-12244]



-----------------------------------------------------------------------



DEPARTMENT OF DEFENSE

Defense Science Board 1995 Summer Study Task Force on Technology 
Investments for 21 Century Military Superiority

ACTION: Notice of Advisory Committee meetings.

-----------------------------------------------------------------------

SUMMARY: The Defense Science Board 1995 Summer Study Task Force on 
Technology Investments for 21st Century Military Superiority will meet 
in closed session on August 6-18, 1995 at the Beckman Center, Irvine, 
California.
    The mission of the Defense Science Board is to advise the Secretary 
of Defense through the Under Secretary of Defense for Acquisition and 
Technology on scientific and technical matters as they affect the 
perceived needs of the Department of Defense. At this meeting the Task 
Force will focus on those R&D investments that must be made now so as 
to assure a technology base in the year 2000 capable of providing U.S. 
military superiority in the 21st century.
    In accordance with Section 10(d) of the Federal Advisory Committee 
Act, P.L. No. 92-463, as amended (5 U.S.C. App. II, (1988)), it has 
been determined that this DSB Task Force meeting, concerns matters 
listed in 5 U.S.C. Sec. 552b(c)(1) (1988), and that accordingly this 
meeting will be closed to the public.

    Dated: May 15, 1995.
Patricia L. Toppings,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 95-12244 Filed 5-17-95; 8:45 am]
BILLING CODE 5000-04-M
<PAGE>

                                                                    EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal American Financial Corp.
(the "Company") on Form 10-Q for the period ending September 30, 2003 as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Richard A. Barasch, Chief Executive Officer of the Company, certify, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

         (1) The Report fully complies with the requirements of section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.

Date: November 14, 2003

                                       /s/ Richard A. Barasch
                                       -----------------------------------------
                                       Richard A. Barasch
                                       Chief Executive Officer

                                       47
---

EXHIBIT 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

PURSUANT TO18 U.S.C. SECTION 1350,AS
ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of All American Gold Corp.
(the Company) on Form 10-KA for the year ended May 31, 2013, as filed with the
Securities and Exchange Commission on the date hereof (the Annual Report), I,
Gaspar R. Gonzalez, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

|1. | the Annual Report fully complies with the requirements of
      Section 13(a) or 15(d) of the Securities Exchange Act of 1934;
  and                                   
|-- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------
|   |                                                                                                                                                                        
|2. | the information contained in the Annual Report fairly
      presents, in all material respects, the financial condition and results of
      operations of the Company.

Dated: November 8, 2013

/s/ Gaspar R. Gonzalez
  Gaspar R. Gonzalez 
  Chief Executive
Officer

A signed original of this written statement required by Section
906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this
written statement required by Section 906, has been provided to All American
Gold Corp. and will be retained by All American Gold Corp. and furnished to the
Securities and Exchange Commission or its staff upon request.

---
Order filed March 19, 2013 

In The

Fourteenth Court of Appeals

____________

NO. 14-13-00216-CV

____________

JAY H. COHEN, INDIVIDUALLY AND AS TRUSTEE OF THE JHC 

TRUST I AND II, Appellant

V.

NEWBISS PROPERTY, L.P., Appellee

On Appeal from the 234th District Court

Harris County, Texas

Trial Court Cause No. 2010-20973A

ORDER

This is an appeal from a judgment signed February 8, 2013. Related cases 

were previously filed in the Court of Appeals for the First District of Texas under 

case numbers 01-10-00804-CV and 01-11-00544-CV.

It is ORDERED that the appeal docketed under this court=s appellate cause 

number 14-13-00216-CV is transferred to the Court of Appeals for the First 

District of Texas pursuant to Local Rule 1.5. 14th Tex. App. (Houston) Loc. R. 
1.5. The Clerk of this Court is directed to transfer all papers filed in the case, and 

certify all Orders made, to the Court of Appeals for the First District of Texas.

PER CURIAM
Exhibit
        32.1
 
 CERTIFICATION
        PURSUANT TO
 18
        U.S.C.
        SECTION 1350,
 AS
        ADOPTED PURSUANT TO
 SECTION
        906 OF THE SARBANES-OXLEY ACT OF 2002
 
 Each
        of
        the undersigned hereby certifies, in his capacity as an officer of Fushi
        Copperweld, Inc. (the "Company"), for the purposes of 18 U.S.C. Section 1350,
        as
        adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to
        the
        best of his knowledge:
 
 (1)
        The
        Quarterly Report of the Company on Form 10-Q for the quarter ended September
        30,
        2007 fully complies with the requirements of Section 13(a) or 15(d) of the
        Securities Exchange Act of 1934; and
 
 (2)
        The
        information contained in the Report fairly presents, in all material respects,
        the financial condition and results of operations of the Company.
 
 Dated:
        November 14, 2008
 
 /s/
                  Li FuLi
                  FuChief
                  Executive Officer/s/
                  Wenbing Chris WangWenbing
                  Chris WangChief
                  Financial Officer
   A
        signed
        original of this written statement required by Section 906 has been provided
        to
        Fushi Copperweld, Inc. and will be retained by Fushi Copperweld, Inc. and
        furnished to the Securities and Exchange Commission or its staff upon
        request.
UNIFORM TERMS

APPENDIX C

DECEMBER 2023 - APPROVED DRUG PRODUCTS LIST

C-1

Note: Terms comprise currently marketed products

DOSAGE FORMS

AEROSOL, FOAM

AEROSOL, METERED

CAPSULE

CAPSULE, DELAYED REL PELLETS

CAPSULE, DELAYED RELEASE

CAPSULE, EXTENDED RELEASE

CAPSULE, PELLETS

CAPSULE, TABLET

CAPSULE, TABLET, TABLET

CLOTH

CONCENTRATE

CREAM

CREAM, AUGMENTED

CREAM, INSERT

ELIXIR

EMULSION

ENEMA

FILM

FILM, EXTENDED RELEASE

FOAM

FOR SOLUTION

FOR SUSPENSION

FOR SUSPENSION, DELAYED RELEASE

FOR SUSPENSION, EXTENDED RELEASE

GAS

GEL

GEL, AUGMENTED

GEL, METERED

GRANULE

GRANULE, DELAYED RELEASE

GRANULES

GRANULES, EXTENDED RELEASE

GUM, CHEWING

IMPLANT

INHALANT

INJECTABLE

INJECTABLE, LIPID COMPLEX

INJECTABLE, LIPOSOMAL

INJECTION, EXTENDED RELEASE

INSERT

INSERT, EXTENDED RELEASE

INTRAUTERINE DEVICE

JELLY

LIQUID

LOTION

LOTION, AUGMENTED

LOTION/SHAMPOO

OIL

OIL/DROPS

OINTMENT

OINTMENT, AUGMENTED

PASTE

PATCH

PELLET

PELLETS

POWDER

POWDER, EXTENDED RELEASE

POWDER, METERED

RING

SHAMPOO

SOLUTION

SOLUTION FOR SLUSH

SOLUTION, EXTENDED RELEASE

SOLUTION, GEL FORMING/DROPS

SOLUTION, METERED

SOLUTION/DROPS

SPONGE

SPRAY

SPRAY, METERED

SUPPOSITORY

SUSPENSION

SUSPENSION, EXTENDED RELEASE

SUSPENSION, LIPOSOMAL

SUSPENSION/DROPS

SWAB

SYRUP

SYSTEM

TABLET

TABLET, CHEWABLE

TABLET, DELAYED RELEASE

TABLET, EFFERVESCENT

TABLET, EXTENDED RELEASE

TABLET, EXTENDED RELEASE,

CHEWABLE

TABLET, FOR SUSPENSION

TABLET, ORALLY DISINTEGRATING

TABLET, ORALLY DISINTEGRATING,

DELAYED RELEASE

TABLET, ORALLY DISINTEGRATING,

EXTENDED RELEASE

TAPE

TROCHE/LOZENGE
UNIFORM TERMS

APPENDIX C

DECEMBER 2023 - APPROVED DRUG PRODUCTS LIST

C-2

Note: Terms comprise currently marketed products

ROUTES OF ADMINISTRATION

BUCCAL

CARDIAC

DENTAL

ENDOCERVICAL

ENDOTRACHEAL

ENTERAL

IMPLANTATION

INFILTRATION

INHALATION

INJECTION

INTERSTITIAL

INTRA-ANAL

INTRA-ARTERIAL

INTRA-ARTICULAR

INTRACAMERAL

INTRACAVITARY

INTRACRANIAL

INTRADERMAL

INTRAMUSCULAR

INTRAOCULAR

INTRAOSSEOUS

INTRAPERITONEAL

INTRAPLEURAL

INTRATHECAL

INTRAUTERINE

INTRAVENOUS

INTRAVESICAL

INTRAVITREAL

IRRIGATION

IV (INFUSION)

N/A

NASAL

OPHTHALMIC

ORAL

ORAL-21

ORAL-28

OTIC

PERFUSION

PERIARTICULAR

PERIODONTAL

PYELOCALYCEAL

RECTAL

SPINAL

SUBCUTANEOUS

SUBLINGUAL

TOPICAL

TRANSDERMAL

TRANSMUCOSAL

URETHRAL

VAGINAL
UNIFORM TERMS

APPENDIX C

DECEMBER 2023 - APPROVED DRUG PRODUCTS LIST

C-3

ABBREVIATIONS

AMP AMPULE

AMPICIL AMPICILLIN

APPROX APPROXIMATELY

BOT BOTTLE

CI CURIE

CSR CAROTID SINUS REFLEX

CU CLINICAL UNITS

DIPROP DIPROPIONATE

ELECT ELECTROLYTE

EQ EQUIVALENT TO

ER EXTENDED RELEASE

GM GRAM

HBR HYDROBROMIDE

HCL HYDROCHLORIDE

HR HOUR

IM INTRAMUSCULAR

INH INHALATION

IU INTERNATIONAL UNITS

IV INTRAVENOUS

KIU KALLIKREIN INHIBITOR UNITS

MCG MICROGRAM

MCI MILLICURIE

MEQ MILLIEQUIVALENT

MG MILLIGRAM

ML MILLILITER

N/A NOT APPLICABLE

PPM PARTS PER MILLION

REL RELEASE

SC SUBCUTANEOUS

SQ CM SQUARE CENTIMETER

U UNITS

UCI MICROCURIE

UMOLAR MICROMOLAR

USP UNITED STATES PHARMACOPEIA
Exhibit 4 

Case 3:17-cv-00939-WHA Document 1691-5 Filed 09/19/17 Page 1 of 3
1

From: Melanie.Blunschi@lw.com

Sent: Tuesday, September 19, 2017 10:50 AM

To: Jeff Nardinelli; Andrea P Roberts; David Perlson; QE-Waymo;

UberWaymoMoFoAttorneys@mofo.com; BSF_EXTERNAL_UberWaymoLit@bsfllp.com;

DG-GPOttoTruckingWaymo@goodwinlaw.com; miles@ramsey-ehrlich.com;

amy@ramsey-ehrlich.com; jpatchen@taylorpatchen.com;

kdhadialla@taylorpatchen.com; dbrownstein@fbj-law.com; wfarmer@fbj-law.com;

mpernick@mkwllp.com; jbartlett@mkwllp.com; af@annefokstuen.com

Cc: Whitney.Weber@lw.com; Stephanie.Strider@lw.com; John.Eastly@LW.com

Subject: RE: Stroz review at Latham tomorrow

Categories: Waymo

Counsel,

In response to David’s various emails about the number of screened documents, please see the below

document counts. If Waymo would like to run search terms in the private documents, please provide us with

those terms, and Stroz will stage the responsive materials for each diligenced employee’s counsel’s review to

determine to what extent they will either agree to production or escalate documents to the Special Master.

Levandowski – 425,317 available docs

Privilege – 3,211

Private – 17,175

Ron – 228,256 available docs

Privilege – 641

Private – 17,134

Burnette – 487,461 available docs

No screened documents

Juelsgaard – 282,329 available docs

Privileged/Private – 18,575

Sebern – 55,743 available docs

Private – 30,175

Melanie M. Blunschi

LATHAM & WATKINS LLP

505 Montgomery Street

Suite 2000

San Francisco, CA 94111-6538

Direct Dial: +1.415.395.8129

Fax: +1.415.395.8095

Email: melanie.blunschi@lw.com

http://www.lw.com

Case 3:17-cv-00939-WHA Document 1691-5 Filed 09/19/17 Page 2 of 3
2

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the

intended recipient. Any review, disclosure, reliance or distribution by others or forwarding without express permission is

strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies including any

attachments.

Latham & Watkins LLP or any of its affiliates may monitor electronic communications sent or received by our networks in

order to protect our business and verify compliance with our policies and relevant legal requirements.

Latham & Watkins LLP

Case 3:17-cv-00939-WHA Document 1691-5 Filed 09/19/17 Page 3 of 3
<PAGE>

                                                                    Exhibit 10.2

                           [incuVest LLC Letterhead]

                                                              590 Madison Avenue
                                                              New York, NY 10022
                                                              Main: 212.849.8160
                                                               Fax: 212.849.8171
                                                          corporate@incuVest.com
                                                                www.incuVest.com

August 16, 2000

Board of Directors
AXCESS Inc.
3208 Commander Drive
Carrollton, TX 75093

Gentlemen:

This letter is to inform you of incuVest LLC commitment to subscribe to 500
shares of Series 2000A Preferred Stock as described in your August 14, 2000
offering memorandum.  Additionally we will introduce AXCESS to other accredited
investors that might have an interest in subscribing to this offering.

Please contact me if you have any questions regarding incuVest's commitment.  I
look forward to continued success with AXCESS Inc.

Sincerely,

/s/ Robert Bertoldi

Robert Bertoldi
President
incuVest LLC
2004 Annual Incentive Program Summary



 Exhibit 10(d) 
  
 2004 Annual Incentive Program Summary 
  
 Summary 
  
 Magellan’s 2004 annual incentive program has been established to motivate individual activities that will improve the overall performance of the company. Metrics
have been identified and targets set in several performance categories, including financial and operational categories. In addition, a funding metric has been established that sets a floor of performance for the partnership below which no payout for
any metric will be made. This mechanism reflects the view of management that it is inappropriate to pay bonuses if the overall cash generation of Magellan drops very significantly for any reason. 
  
 The 2004 program payout will be based on a combination of: 
  

	 	•	Partnership performance 


	 	•	Individual performance 

  
 Threshold, target and stretch levels of achievement have been set for each metric. Payouts under the plan begin after the threshold level of performance is achieved. Target payout occurs when results reach targeted
performance expectations and the maximum payout occurs if results reach the stretch targets. 
  
 Payouts at the target performance level are based on a percentage of employee eligible earnings. Eligible earnings include regular base pay and eligible overtime pay for the period in which an employee is a
participant in the plan, including, but not limited to, hours worked during a normal workday, PTO, short term disability, holiday pay, jury duty pay, bereavement pay and shift differentials. 
  
 If target performance is achieved, 100% of the calculated payout is eligible to be paid under
the program. If stretch performance is achieved, 200% of the calculated payout is eligible to be paid. The calculated payout percentage for performance between threshold and target, or between target and stretch, will be prorated. 
  
 Fifty percent (50%) of the calculated payout is subject to a personal performance adjustment.
The personal performance adjustment applied to that 50% of the calculated payment can range from 0% of that 50% to 200% of that 50%. 
  
 Eligible employees begin participating in the plan on the first day of employment in the plan year. To be eligible to receive an award, an employee must be employed
during the plan year including the last day of the plan year and through the time the award is actually paid. Exceptions to this requirement will be made where a participant’s employment is terminated as a result of retirement or death, or the
participant becomes eligible for long-term disability after the first day of the plan year but before the award is paid. Such employees will be eligible for a prorated award based on the portion of the year worked prior to the employment termination
event. A participant whose employment is terminated anytime prior to the distribution of the award under any other circumstances is not eligible for an award.
Lester L. WASHINGTON, petitioner, v. NATIONAL EDUCATION ASSOCIATION, et al.

No. 12-9033.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Michael Keith DAUGHERTY, petitioner, v. THE HEIGHTS, et al.

No. 12-8253.

Supreme Court of the United States

May 13, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Verdell REESE, petitioner, v. MICHIGAN.

No. 12-8904.

Supreme Court of the United States

April 29, 2013.

Petition for writ of certiorari to the Court of Appeals of Michigan denied.
Sự Bùng Phát Của Một Căn Bệnh Do Thức Ăn Có Thể Đã Được Ngăn Ngừa

Con tôi, Manuel, đã bị sốt và tiêu chảy và tôi đã Tôi phải đi làm hoặc có nguy cơ mất việc. Tôi thật sự muốn mình có thể ở nhà với Manuel. Tôi đã rất 

thức cả đêm để chăm sóc cậu bé. Sáng hôm sau, lo trong suốt thời gian đang làm việc.

tôi có lịch làm việc.

Mary đang thưởng thức bữa trưa với Bố mình. Bánh mì có mùi vị rất ngon, nhưng Mary không biết cô Ngày sau đó, những người mà tôi đã phục vụ than 

đang ăn cái gì khác nữa. phiền về việc bị ốm vì nôn mửa và tiêu chảy.

Mary, người có hệ miễn dịch yếu, đã ốm rất nặng. Một vài ngày sau đó, Mary đã phải đi cấp cứu. 25 Tôi không có ý làm cho bất cứ ai bị bệnh. Giờ thì, do 

người đã bị tiêu chảy và nôn mửa. Nhà hàng đã những mầm bệnh trên tay tôi, người nào đó có thể bị 

đóng cửa và tôi mất việc. chết.

Hãy Bảo Vệ Mọi Người Ở Mọi Nơi. Rửa sạch tay thật kỹ vào những lúc thích hợp. 

Không chạm vào thức ăn làm sẵn bằng tay trần.
Terry Gene FREEMAN, petitioner, v. William STEPHENS, Director, Texas Department of Criminal Justice, Correctional Institutions Division.

No. 12-10087.

Supreme Court of the United States

Dec. 2, 2013.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Michael Ramon OCHOA, petitioner, v. Erin RUBIN, aka Erin Rubin Ochoa.

No. 12-732.

Supreme Court of the United States

April 15, 2013.

Petition for rehearing denied.
```

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[S. Res. 851 Introduced in Senate (IS)]

<DOC>

117th CONGRESS
  2d Session
S. RES. 851

Celebrating the 45th anniversary of the Senate Black Legislative Staff 
               Caucus and its achievements in the Senate.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                           November 29, 2022

Mr. Scott of South Carolina (for himself, Mr. Booker, and Mr. Warnock) 
submitted the following resolution; which was referred to the Committee 
                      on Rules and Administration

_______________________________________________________________________

                               RESOLUTION

 
Celebrating the 45th anniversary of the Senate Black Legislative Staff 
               Caucus and its achievements in the Senate.

Whereas, in 1977, Jackie Parker and Ralph Everett had the vision and courage to 
        improve the working conditions of Black Senate staffers;
Whereas the Senate Black Legislative Staff Caucus continues to promote diversity 
        and inclusion within the Senate;
Whereas the Senate Black Legislative Staff Caucus recognizes each of the 11 
        current or former Senators of African-American descent;
Whereas the Senate Black Legislative Staff Caucus celebrates and commemorates 
        the dedicated efforts of its members to promote a more diverse and 
        representative government; and
Whereas the Senate Black Legislative Staff Caucus continues to fight for the 
        justice and equality that started during the civil rights movement of 
        the 1960s: Now, therefore, be it
    Resolved, That the Senate honors the Senate Black Legislative Staff 
Caucus for its many contributions and commitment to enrich the Senate 
community.
                                 <all>
```
Candy S. BRADISON, petitioner, v. MINNESOTA COMMISSIONER OF REVENUE.

No. 12-1337.

Supreme Court of the United States

Aug. 12, 2013.

Petition for rehearing denied.
In Re Robert HEXIMER, petitioner.

No. 12-9595.

Supreme Court of the United States

Aug. 30, 2013.

Motion for leave to file a petition for rehearing denied.
Exhibit 32.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER  PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906  OF THE SARBANES-OXLEY ACT
OF 2002

I, Gene Austin, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that the annual report of Convio, Inc., on Form 10-K for the period ended December 31, 2010 fully complies with the requirements of Section 13(a) or
15(d), as applicable, of the Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and
results of operations of Convio, Inc.

Date: March 11, 2011

/s/ GENE AUSTIN Gene Austin Chief Executive Officer (Principal Executive Officer), President and Chairman of the Board of Directors


I,
James R. Offerdahl, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the annual report of
Convio, Inc., on Form 10-K for the period ended December 31, 2010 fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the
Securities Exchange Act of 1934 and the information contained in such Form 10-K fairly presents, in all material respects, the financial condition and results of operations of
Convio, Inc.

Date: March 11, 2011

/s/ JAMES R. OFFERDAHL James R. Offerdahl Chief Financial Officer and Vice President of Administration (Principal Financial and
Accounting Officer)


A
signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Convio, Inc. and will be retained by
Convio, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This certification "accompanies" the Form 10-K to which it relates, is not
deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.

---



QuickLinks
John Theodore ANDERSON, petitioner, v. PRIVATE CAPITAL GROUP, et al.

No. 12M113.

Supreme Court of the United States

April 29, 2013.

Motion for leave to proceed as a veteran denied.